Veltassa

Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Wed, 05/10/23 - 10:18 am
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study
Pharmaceutical Business Review
Mon, 05/13/19 - 09:25 am
Vifor
hypertension
chronic kidney disease
Veltassa
clinical trials
Galenica to Buy Relypsa for $1.53 Billion
TheStreet.com
Thu, 07/21/16 - 09:05 am
Galenica
Relypsa
M&A
Veltassa
A Great Month For Relypsa
Seeking Alpha
Sat, 05/28/16 - 10:38 am
Relypsa
AstraZeneca
Veltassa
hyperkalemia
ZS-9
3 Big Battles Brewing in Biotech
Motley Fool
Sun, 04/10/16 - 01:50 pm
AstraZeneca
ZS-9
Relypsa
Veltassa
Synergy Pharmaceuticals
plecanatide
Linzess
Ironwood
Allergan
Incyte
Eli Lilly
baricitinib
AbbVie
Humira
Relypsa Rises on Bullish Veltassa Report; AstraZeneca, Sanofi Take Note
Bidness, ETC
Fri, 02/12/16 - 04:08 pm
Relypsa
Veltassa
AstraZeneca
Sanofi
Relypsa's Veltassa Will Be Embraced By Physicians
Seeking Alpha
Thu, 10/22/15 - 07:25 pm
Relypsa
Veltassa
physicians
hyperkalemia